PDL stock: buy or sell?
August 22nd, 2019
PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally.
Should I buy PDL stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, PDL stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is PDL stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for PDLI stock for the last month.
PDL stock analysis
PDL BioPharma slipped a shocking -2.69% and closed at $2.53.
PDL ended yesterday at $2.53 and slipped a shocking -2.69%. For the last 32 days when PDLI stock price broke down the SMA200d line, it slid $-0.61 per share (-19.43%).
After sliding a bloodcurdling -6.25% in a week last week, PDL closed this week at $2.53 and declined a bad -1.17%. For 5 weeks in a row, price slid and lost a -19.49%.
The support failed to resist and PDLI sinked deeper.
PDL stock price history
PDL IPO was on January 29th, 1992 at $0.86 per share1. Since then, PDLI stock surged a 194.20%, with a yearly average of 7.20%. If you had invested $1,000 in PDL stock in 1992, it would worth $1,942.00 today.
1: Adjusted price after possible price splits or reverse-splits.
PDL stock historical price chart
PDLI stock reached 52-week highs on April at $3.89, and all-time highs 2000-03-07 with a price of 15.51.
PDL stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price forecast for PDL stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, PDL BioPharma presented its financial report, posting an exceptional gain for the Earnings per Share (EPS) ratio. Experts were expecting $0.08 per share, but PDL BioPharma posted $0.10.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, PDL annual turnover plunged a frightening -21.05% to $110.52 million USD from $139.99 marked in 2017. When comparing 2018 vs 2017, in line, profit margin (that is, the net income divided by revenues) plummed a -141.42% to -62.31%.
|2013||$444 M||-||$265 M59.5%||-|
|2014||$533 M||19.98%||$322 M60.4%||21.82%|
|2015||$486 M||-8.88%||$333 M68.5%||3.27%|
|2016||$198 M||-59.31%||$64 M32.2%||-80.89%|
|2017||$140 M||-29.19%||$111 M79.1%||74.12%|
|2018||$111 M||-21.05%||$-68.86 M-62.3%||-162.18%|
Quarterly financial resultsPDL posted $25.90 million in revenues for 2018-Q4, a 3.75% up compared to previous quarter. Reported quarter income marked $16.28 million with a profit margin of 62.86%. Profit margin collapsed a -39.53% compared to previous quarter when profit margin was 102.39%. When comparing sales to same quarter last year, PDL BioPharma sales marked a hair-raising correction and plummed a -48.51%.
|2017-Q1||$45 M||-||$7.24 M15.9%||-|
|2017-Q2||$144 M||216.55%||$60.44 M42.0%||734.81%|
|2017-Q3||$57 M||-60.58%||$20.73 M36.6%||-65.70%|
|2017-Q4||$50 M||-11.30%||$22.34 M44.4%||7.74%|
|2018-Q1||$27 M||-46.95%||$1.60 M6.0%||-92.83%|
|2018-Q2||$33 M||23.63%||$-112.30 M-340.5%||-7,109.74%|
|2018-Q3||$25 M||-24.32%||$25.56 M102.4%||-122.76%|
|2018-Q4||$26 M||3.75%||$16.28 M62.9%||-36.30%|
PDL ownershipWhen you are planning to buy shares of a stock, it's worth to overview its ownership structure.
PDL BioPharma shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 2.47% of all shares.
Bearish positions for PDLI stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to PDL BioPharma:
|Market cap||$305.3 M||$124.1 B||$252.1 M||$121.7 B||$9.8 B|
|Total shares||120.7 M||609.9 M||62.4 M||1,090.0 M||515.5 M|
|Float shares||108.6 M||598.3 M||59.5 M||796.0 M||512.8 M|
|- Institutional holdings (%)||95.2%||81.9%||20.2%||81.5%||86.2%|
|- Insider holdings (%)||2.5%||0.2%||4.0%||0.1%||1.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$2.46 - $2.61|
|Average true range||$0.12|
|50d mov avg||$2.95|
|100d mov avg||$3.12|
|200d mov avg||$3.16|
PDL performanceTo better understand PDL performance you must compare its gains with other related stocks in same sector or industry. For PDL BioPharma, the benchmark is made against Amgen, Compugen, Eli Lilly and, Mylan, Nektar and Sangamo Therapeutics.
|LLYEli Lilly and||-3.90%||-8.98%||7.83%|